Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2007-11-27
2007-11-27
Wehbe′, Anne M. (Department: 1632)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C536S023100, C424S093200, C514S04400A
Reexamination Certificate
active
11143986
ABSTRACT:
The present invention relates to novel vaccines against malaria infections, based on recombinant viral vectors, such as alpha viruses, adenoviruses or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against differentPlasmodiuminfections, such as infections byP. falciparumorP. yoelii.Novel codon-optimized circumsporozoite genes are disclosed. Preferably, replication-defective adenoviruses are used, derived from serotypes that encounter low titers of neutralizing antibodies. The invention, therefore, also relates to the use of different adenoviral serotypes that are administered to elicit a strong immune response, either in single vaccination set-ups or in prime-boost set-ups in which compositions based on different serotypes can be applied.
REFERENCES:
patent: 6306625 (2001-10-01), Jacobs et al.
patent: 99201545.3 (1999-05-01), None
patent: 0 978 566 (2000-02-01), None
patent: 1054064 (2000-11-01), None
patent: WO 93/10152 (1993-05-01), None
patent: WO 96/26281 (1996-08-01), None
patent: WO 96/39178 (1996-12-01), None
patent: WO 97/00326 (1997-01-01), None
patent: WO 98/32842 (1998-07-01), None
patent: WO 98/50053 (1998-11-01), None
patent: WO 99/55132 (1999-11-01), None
patent: WO 99/64582 (1999-12-01), None
patent: WO 00/03029 (2000-01-01), None
patent: WO 00/52186 (2000-09-01), None
patent: WO 00/70071 (2000-11-01), None
patent: WO 01/02607 (2001-01-01), None
patent: WO 01/05945 (2001-01-01), None
patent: WO 01/07571 (2001-02-01), None
patent: WO 02/22080 (2002-03-01), None
patent: WO 02/24730 (2002-03-01), None
patent: WO 02/40665 (2002-05-01), None
patent: WO 2004/055187 (2004-07-01), None
Soares and Rodrigues 1998, Brazilian Journal of Medical and Biological Research 31: 317-332.
Miyahara et al., 1998, PNAS, USA, 95: 3954-3959.
Narum et al., 2001, Infection and Immunity, 69: 7250-7253.
Tine et al., 1996, Infection and Immunity, 64: 3833-3844.
Singh and O'Hagan, 1999, Nature Biotechnology, 17: 1075-1081.
PCT International Search Report, PCT/EP03/51019, dated Jun. 9, 2004.
Miyahira et al., “Recombinant viruses expressing a human malaria antigen can elicit potencially protective immune CD8+ responses in mice,” Proc. Natl. Acad. Sci. USA, Mar. 31, 1998, pp. 3954-3959, vol. 95, No. 7.
Bruna-Romero et al., “Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen,” Proc. Natl. Acad Sci. USA, Sep. 25, 2001, pp. 11491-11496, vol. 98, No. 20.
Nagata et al., “Codon Optimization Effect on Translational Efficiency of DNA Vaccine in Mammalian Cells: Abakysis of Plasmid DNA Encoding a CTL Epitope Derived from Microorganisms,” Aug .2, 1999, pp. 445-451, vol. 261, No. 2.
Scheiblhofer et al., “Removal od the circumsporosoite protein (CSP) glycosylphosphatidylinositol signal sequence from a CSP DNA vaccine enhances induction of CSP-specifit Th2 type immune responses and improves protection against malaria infection,” Eur. J. Immunol., Mar. 2001, pp. 692-698, vol. 31, No. 3.
Daubersies et al., “Protection againstPlasmodium falciparummalaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3,” Nature Medicine, Nov. 2000, pp. 1258-1263, vol. 6, No. 11.
Narum et al., “Codon Optimization of Gene Framents EncodingPlasmodium falciparumMerzoite Proteins Enhances DNA Vaccine Protein Expression and Immunogenicity in Mice,” Dec. 2001, pp. 7250-7253vol. 69, No. 12.
Benmohamed et al., “High immunogenicity in chimpanzees of peptides and lipopeptides derived from four newPlasmodium falciparumpre-erythrocytic molecules,” Jun. 2000, pp. 2843-2855, vol. 18, No. 25.
Basler et al., “Sequence of the immunoregulatory early region 3 and flanking sequences of adenovirus type 35,” Gene, 1996, pp. 249-254, vol. 170.
Flomenberg et al., “Molecular Epidemiology of Adenovirus Type 35 Infections in Immunocompromised Hosts,” The Journal of Infectious Diseases, Jun. 1987, pp. 1127-1134, vol. 155, No. 6.
Flomenberg et al., “Sequence and genetic Organization of Adenovirus Type 35 Early Region 3,” Journal of Virology, Nov. 1988, pp. 4431-4437, vol. 62, No. 11.
Gahery-Segard et al., “Immune response to recombinant Capsid Proteins of Adenovirus in Humans: Antifiber and Anti-Penton Base Antibodies Have a Synergistic Effect on Neutralizing Activity,” Journal of Virology, Mar. 1998, pp. 2388-2397, vol. 72, No. 3.
Kang et al., “Molecular Cloning and Physical Mapping of the DNA of Human Adenovirus Type 35,” Acta Microbiologica Hungarica, 1999, pp. 67-75, vol. 36, No. 1.
Krasnykh et al., “Generation of Recombinant Adenovirus Vectors with modified Fibers for Altering Viral Tropism,” Journal of Virology, Oct. 1996, pp. 6839-3846, vol. 70, No. 10.
Notice of Opposition to a European Patent, Patent No. 1054064, by Cell Genesys Inc., dated Jul. 5, 2005.
Rosenfeld et al., Adenovirus-Mediated Transfer of a recombinant alpha-1-Antitrypsin Gene to the Lung Epithelium in Vivo, Science, Apr. 19, 1991, pp. 431-434, vol. 252.
Roy et al., “Circumvention of Immunity to the Adenovirus major Coat Protein Hexon,” Journal of Virology, Aug. 1998, pp. 6875-6879, vol. 72, No. 8.
Stevenson et al., “Human Adenovirus Serotypes 3 and 5 Bind to Two Different Cellular receptors via the Fiber Head Domain,” Journal of Virology, May 1995, pp. 2850-2857, vol. 69, No. 5.
Stratford-Perricaudet et al., “Evaluation of the Transfer and Expression in Mice of an Enzyme-Encoding Gene Using a Human Adenovirus Vector,” Human Gene Therapy, 1990, pp. 241-256, vol. 1.
Holterman Lennart
Kaspers Jorn
Pau Maria G.
Stegmann Antonius J. H.
Crucell Holland B.V.
Hama Joanne
TraskBritt
Wehbe′ Anne M.
LandOfFree
Recombinant viral-based malaria vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant viral-based malaria vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant viral-based malaria vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3835319